You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 293 No. 19, May 18, 2005 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Original Contribution
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (59)
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Women's Contraception
 •Venous Thromboembolism
 •Alert me on articles by topic

Thrombophilia, Clinical Factors, and Recurrent Venous Thrombotic Events

Sverre C. Christiansen, MD; Suzanne C. Cannegieter, MD, PhD; Ted Koster, MD, PhD; Jan P. Vandenbroucke, MD, PhD; Frits R. Rosendaal, MD, PhD

JAMA. 2005;293:2352-2361.

Context  Data on the recurrence rate of venous thrombotic events and the effect of several risk factors, including thrombophilia, remain controversial. The potential benefit of screening for thrombophilia with respect to prophylactic strategies and duration of anticoagulant treatment is not yet known.

Objectives  To estimate the recurrence rate of thrombotic events in patients after a first thrombotic event and its determinants, including thrombophilic abnormalities.

Design, Setting, and Patients  Prospective follow-up study of 474 consecutive patients aged 18 to 70 years without a known malignancy treated for a first objectively confirmed thrombotic event at anticoagulation clinics in the Netherlands. The Leiden Thrombophilia Study (LETS) was conducted from 1988 through 1992 and patients were followed up through 2000.

Main Outcome Measures  Recurrent thrombotic event based on thrombophilic risk factors, sex, type of initial thrombotic event (idiopathic or provoked), oral contraceptive use, elevated levels of factors VIII, IX, XI, fibrinogen, homocysteine, and anticoagulant deficiencies.

Results  A total of 474 patients were followed up for mean (SD) of 7.3 (2.7) years and complete follow-up was achieved in 447 (94%). Recurrence of thrombotic events occurred in 90 patients during a total of 3477 patient-years. The rate of thrombotic event recurrence was 25.9 per 1000 patient-years (95% confidence interval [CI], 20.8-31.8 per 1000 patient-years). The incidence rate of recurrence was highest during the first 2 years (31.9 per 1000 patient-years; 95% CI, 20.3-43.5 per 1000 patient-years). The risk of thrombotic event recurrence was 2.7 times (95% CI, 1.8-4.2 times) higher in men than in women. Patients whose initial thrombotic event was idiopathic had a higher risk of a thrombotic event recurrence than patients whose initial event was provoked (hazard ratio [HR], 1.9; 95% CI, 1.2-2.9). Women who used oral contraceptives during follow-up had a higher thrombotic event recurrence rate (28.0 per 1000 patient-years; 95% CI, 15.9-49.4 per 1000 patient-years) than those who did not (12.9 per 1000 patient-years; 95% CI, 7.9-21.2 per 1000 patient-years). Recurrence risks of a thrombotic event by laboratory abnormality ranged from an HR of 0.6 (95% CI, 0.3-1.1) in patients with elevated levels of factor XI to an HR of 1.8 (95% CI, 0.9-3.7) for patients with anticoagulant deficiencies.

Conclusions  Prothrombotic abnormalities do not appear to play an important role in the risk of a recurrent thrombotic event. Testing for prothrombotic defects has little consequence with respect to prophylactic strategies. Clinical factors are probably more important than laboratory abnormalities in determining the duration of anticoagulation therapy.


Author Affiliations: Departments of Clinical Epidemiology (Drs Christiansen, Cannegieter, Koster, Vandenbroucke, and Rosendaal) and Hematology (Dr Rosendaal), Leiden University Medical Center, Leiden, the Netherlands.


RELATED LETTERS

Clinical Factors and Recurrent Venous Thrombotic Events
Bradley Flansbaum
JAMA. 2005;294(12):1489.
EXTRACT | FULL TEXT  

Clinical Factors and Recurrent Venous Thrombotic Events—Reply
Suzanne C. Cannegieter and Frits R. Rosendaal
JAMA. 2005;294(12):1489-1490.
EXTRACT | FULL TEXT  

RELATED ARTICLE

Clinical Factors and Recurrent Venous Thrombotic Events—Reply
Suzanne C. Cannegieter and Frits R. Rosendaal
JAMA. 2005;294(12):1489-1490.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Update in Hematology
DeLoughery
ANN INTERN MED 2007;147:717-724.
FULL TEXT  

Venous thrombosis in the elderly: more questions than answers
Silverstein et al.
Blood 2007;110:3097-3101.
FULL TEXT  

Risk of recurrence after a first venous thromboembolic event in young women
Laczkovics et al.
haematol 2007;92:1201-1207.
ABSTRACT | FULL TEXT  

The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies
Marchiori et al.
haematol 2007;92:1107-1114.
ABSTRACT | FULL TEXT  

Response: Homocysteine lowering and recurrent venous thrombosis: the VITRO trial
den Heijer et al.
Blood 2007;109:5521-5522.
FULL TEXT  

Relevance of Genetics and Genomics for Prevention and Treatment of Cardiovascular Disease: A Scientific Statement From the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group
Arnett et al.
Circulation 2007;115:2878-2901.
ABSTRACT | FULL TEXT  

Haematology and neurology
Austin et al.
J. Neurol. Neurosurg. Psychiatry 2007;78:334-341.
ABSTRACT | FULL TEXT  

The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients
Prandoni et al.
haematol 2007;92:199-205.
ABSTRACT | FULL TEXT  

Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial
den Heijer et al.
Blood 2007;109:139-144.
ABSTRACT | FULL TEXT  

Testing for thrombophilia: an evidence-based approach
Merriman and Greaves
Postgrad. Med. J. 2006;82:699-704.
ABSTRACT | FULL TEXT  

Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review.
Ho et al.
Arch Intern Med 2006;166:729-736.
ABSTRACT | FULL TEXT  

Male sex, first idiopathic deep venous thrombosis, and oral contraception were risk factors for recurrent venous thrombotic events
Levi
Evid. Based Med. 2006;11:59-59.
FULL TEXT  

Genetic variation in the fibrinogen gamma gene increases the risk for deep venous thrombosis by reducing plasma fibrinogen {gamma}' levels
Uitte de Willige et al.
Blood 2005;106:4176-4183.
ABSTRACT | FULL TEXT  

Clinical Factors and Recurrent Venous Thrombotic Events
Flansbaum
JAMA 2005;294:1489-1489.
FULL TEXT  

Recurrence Rate After a First Venous Thrombosis in Patients With Familial Thrombophilia
Vossen et al.
Arterioscler. Thromb. Vasc. Bio. 2005;25:1992-1997.
ABSTRACT | FULL TEXT  

Risk for Recurrent VT: Clinical Factors More Important Than Thrombophilia
JWatch General 2005;2005:3-3.
FULL TEXT  

Inherited Risk Factors for Venous Thrombosis
Cushman
ASH Education Book 2005;2005:452-457.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2005 American Medical Association. All Rights Reserved.